… business, and president and CEO, Daiichi Sankyo, said: “Enhertu … by AstraZeneca and Daiichi Sankyo. Enhertu is already … underway. AstraZeneca and Daiichi Sankyo entered into a global … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo …

… Business, and President and CEO, Daiichi Sankyo, said, “Enhertu continues … (ADC) discovered by Daiichi Sankyo and being jointly developed … commercialised by AstraZeneca and Daiichi Sankyo. Enhertu is already … made by AstraZeneca to Daiichi Sankyo in 2019 and …

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has … oncology business, and president and chief executive officer, Daiichi Sankyo, added: “Enhertu continues to …

Daiichi Sankyo is growing rapidly thanks to … for 2024. But U.S. chief executive Ken Keller is pretty upfront … ,” said Keller, who serves as CEO of Daiichi Sankyo, Inc., the U.S …

… Business, and President and CEO, Daiichi Sankyo, said: “Enhertu continues … (ADC) discovered by Daiichi Sankyo and being jointly developed … commercialized by AstraZeneca and Daiichi Sankyo. Enhertu is already … made by AstraZeneca to Daiichi Sankyo in 2019 and …

… need-to-know this morning Daiichi Sankyo and AstraZeneca said the FDA … , possibly monthly or even quarterly, CEO Gerrit Klaerner said in an …

… expanded use of AstraZeneca and Daiichi Sankyo’s Enhertu, allowing the drug … ,” said Ken Keller, Daiichi Sankyo’s president and CEO, in a statement. Enhertu …

… ; said the BRC's chief executive Helen Dickinson. “Price cuts and … . In corporate news, AstraZeneca and Daiichi Sankyo's Enhertu has been …

… range of speakers from Daiichi Sankyo Chairman, President, and CEO Ken Keller to … “Medtech in the Making.” Pfizer CEO and Chairman Albert Bourla; Regeneron …

… in a press release from Daiichi Sankyo and AstraZeneca, the manufacturers of … Oncology Business, and President and CEO of Daiichi Sankyo, also said in the …